FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549	
---------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICI	AL OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-0287								
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SCHULMAN AMY W				2. Issuer Name and Ticker or Trading Symbol Cyclerion Therapeutics, Inc. [CYCN]						(Ch	eck all applic	cable) or	Person(s) to Iss	wner		
(Last)	,	irst) ΓHERAPEUTIC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/16/2020							Officer below)	(give title	Other (below)	specify	
301 BINNEY STREET				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)	IDGE M	A	02142									X Form f	led by More	Reporting Perso		
(City)	(S	tate)	(Zip)													
		Tab	le I - Non-De	rivativ	e Se	curities	s Ac	quired, Di	sposed o	of, or Be	neficiall	y Owned				
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 5)			Beneficia	es For ally (D) Following (I) (6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code V	Amount	(A) oi (D)	Price	Transact (Instr. 3 a	ion(s)		(1130.4)	
		-	Γable II - Deri (e.g.					uired, Dis , options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	n Date, Transaction of Code (Instr. Derivative		ve es ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
						(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$4.46	06/16/2020		A		10,000		(1)	06/16/2030	Common Stock	10,000	\$0.00	10,000	D		

Explanation of Responses:

1. The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

Remarks:

/s/ David Slatcher, Attorney-in-

06/18/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).